Eric Libre, MD
Pulmonary Disease · Annandale, VANPI 1710993001
Payments from drug & device makers
Across 702 payments — averaging $429.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$212K
- AstraZeneca$79K
- Johnson & Johnson$3K
- Sanofi$966
- Regeneron Healthcare Solutions, Inc.$805
- Amgen$688
- plus $5K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 230 | $211,976 |
| AstraZeneca | 192 | $79,107 |
| Johnson & Johnson | 13 | $3,382 |
| Sanofi | 42 | $966 |
| Regeneron Healthcare Solutions, Inc. | 17 | $805 |
| Amgen | 26 | $688 |
| Viiv Healthcare Company | 1 | $600 |
| Boehringer Ingelheim | 27 | $574 |
| Genentech USA, Inc. | 22 | $536 |
| United Therapeutics Corporation | 7 | $331 |
| Inari Medical, Inc. | 2 | $313 |
| Insmed, Inc. | 13 | $281 |
| Electromed, Inc. | 11 | $247 |
| Verona Pharma, Inc. | 8 | $235 |
| Actelion Pharmaceuticals US, Inc. | 12 | $233 |
| Grifols USA, LLC | 9 | $221 |
| Shionogi Inc | 15 | $185 |
| Baxter Healthcare | 5 | $126 |
| Mylan Specialty L.p. | 6 | $113 |
| Mallinckrodt Hospital Products Inc. | 3 | $95 |
| Philips North America LLC | 5 | $90 |
| Novartis | 4 | $75 |
| Circassia Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| Pfizer | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Gilead | 3 | $49 |
| Vapotherm Inc | 2 | $41 |
| Bayer | 2 | $39 |
| Shire North American Group Inc | 2 | $34 |
| Merck | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Pulmonx Corporation | 1 | $27 |
| Optinose US, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $15 |
How this compares
$301,754 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Annandale
- Vishal MungalAnnandale$44K
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Hannah MannemCharlottesville$326K
- Ray ShepherdRichmond$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.